ChemLifeIntel
Access
ChemLifeIntel/Companies/Provepharm Inc.

Provepharm Inc.

HIGH RISKHQ: — · Private · Founded —
LISTINGPrivateFOUNDED0
FOCUS THERAPY AREAS
Manufacturer
COMPANY INTELLIGENCE SNAPSHOTlive
0
Manufacturing Sites
2
Intelligence Briefs
1
Active Regulatory Actions
—
HQ Country
NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ
View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Provepharm Inc.
REGULATORY INTELLIGENCE·Recall

Provepharm Inc. Faces Class I Recall of Phenylephrine HCl Injection Over Particulate Matter, Raising Supply Chain Concerns

Provepharm Inc. has initiated a Class I recall of 24,640 vials of Phenylephrine HCl Injection across the U.S. due to particulate matter, posing severe patient safety risks. This marks Provepharm's second recall in recent months, signaling potential systemic quality control deficiencies. Procurement and regulatory teams must immediately assess their supply chain exposure and review Provepharm's quality assurance processes for critical injectable products.

90-Day Activity
ProvepharmDextromethorphan Hbr Guaifenesin Phenylephrine Hcl
PSPriya Subramaniam· Intelligence Analyst
2025-02-26 Recall
REGULATORY INTELLIGENCE·Recall

Provepharm Inc. Initiates Class II Recall of Dihydroergotamine Mesylate Injection Due to Discoloration, Impacting US Supply

Provepharm Inc. has initiated a voluntary Class II recall for 10,800 ampules of Dihydroergotamine Mesylate Injection distributed nationwide in the United States. This action, prompted by discoloration, highlights critical quality control vulnerabilities in pharmaceutical manufacturing. Procurement and regulatory teams must assess supply chain resilience and review internal quality assurance protocols to mitigate similar risks.

90-Day Activity
Provepharm
PSPriya Subramaniam· Intelligence Analyst
2024-12-25